7 min read
Monthly FDA Guidance and Regulatory News Review - April 2026
This April 2026 regulatory update highlights new policies on biomarker validation, expanded access to investigational...
Veristat is proud to be participating at a Rare Disease Workshop on July 18, 2018 taking place at Biogen. Veristat's statitiscal and adaptive design expert, Mark Chang, PhD will be will be speaking about the “Controversies in Rare Disease Trial Designs and Personalized Medicine”.
Mark Chang, PhD, Dr. Chang has over 20 years of experience as a statistician designing and implementing both simple and complex adaptive design trials for rare diseases.
7 min read
May 20, 2026 Veristat Blog
This April 2026 regulatory update highlights new policies on biomarker validation, expanded access to investigational...
3 min read
Apr 27, 2026 Veristat Blog
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...